Journal
BLOOD
Volume 137, Issue 22, Pages 3005-3006Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2021011144
Keywords
-
Categories
Ask authors/readers for more resources
This study demonstrates that modifying standard myeloma treatment based on frailty levels benefits elderly patients with newly diagnosed multiple myeloma by reducing toxicity while maintaining efficacy.
In this issue of Blood, Larocca and colleagues show for the first time that selected elderly patients with newly diagnosed multiple myeloma benefit from modification of standard myeloma treatment based on their level of frailty, which results in lower toxicity while preserving efficacy.(1)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available